SCHEMBL29360103

SCHEMBL29360103

O=C(O)c1ccccc1C(=O)Nc1ccc(-c2ccccc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.79
DHODH Q02127 3/20 0.71
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
MAPT P10636 2/20 0.63
GFER P55789 2/20 0.63
KDM4E B2RXH2 1/20 0.63
HPGD P15428 1/20 0.63
STAT1 P42224 1/20 0.63
SMO Q99835 2/20 0.62
PTPN1 P18031 4/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
ALOX12 P18054 1/20 0.61
CHRNB2 P17787 1/20 0.61
CHRNB4 P30926 1/20 0.61
CHRNA3 P32297 1/20 0.61
CHRNA4 P43681 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336628 1.00 ALDH1A1 (0.79) ALDH1A1DHODHMEN1KMT2AMAPT
SCHEMBL13927135 0.92 ALDH1A1 (0.92) ALDH1A1DHODHMEN1KMT2AGFER
SCHEMBL13927142 0.89 MEN1 (0.74) ALDH1A1DHODHMEN1KMT2AGFER
SCHEMBL1991348 0.88 ALDH1A1 (1.00) ALDH1A1MEN1KMT2AGFERKDM4E
SCHEMBL45299 0.88 ALDH1A1 (1.00) ALDH1A1MEN1KMT2AGFERKDM4E
SCHEMBL18132360 0.87 SMO (0.60) ALDH1A1DHODHMEN1KMT2AHPGD
SCHEMBL15928756 0.87 ALDH1A1 (0.72) ALDH1A1DHODHMEN1KMT2AMAPT
SCHEMBL12189649 0.85 ALDH1A1 (0.85) ALDH1A1MEN1KMT2AMAPTGFER
SCHEMBL2058694 0.85 ALDH1A1 (0.79) ALDH1A1MEN1KMT2AGFERKDM4E
SCHEMBL12046468 0.84 ALDH1A1 (0.66) ALDH1A1DHODHMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746852-A1 LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION Universität Bern (CH) 2026-05-27 EP claimed
CN-121197040-B In-situ carrier hydrogel based on nano bottle packaging technology and preparation method and application thereof 上海大学 2026-05-19 CN claimed
CN-121586573-A Lipopolymers for intra-articular administration 伯尔尼大学 2026-02-27 CN claimed
US-20260041819-A1 TUNABLE, BIOCOMPATIBLE, NANOPARTICLE-CROSSLINKED HYALURONIC ACID-TYPE I COLLAGEN HYDROGEL USING DIELS-ALDER CLICK CHEMISTRY FOR REGENERATIVE MEDICINE APPLICATIONS CLARKSON UNIVERSITY (US) 2026-02-12 US claimed
US-20260023070-A1 OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS UNIV JOHNS HOPKINS (US) 2026-01-22 US claimed
US-20250339520-A1 COMPOSITIONS AND METHODS FOR USE IN KRAS-TARGETED THERAPIES FOR THE TREATMENT OF CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-11-06 US claimed
US-20250295643-A1 METHODS OF TREATING EPILEPSY UNIV YALE (US) 2025-09-25 US claimed
EP-4618966-A2 STABILIZED BLOOD DERIVED COMPOSITION USING ANTIFIBRINOLYTIC AGENTS Turzi, Antoine (CH) 2025-09-24 EP claimed
CN-120053685-A KGN-loaded nano vesicle, dissoluble microneedle and preparation method and application thereof 重庆科技大学 2025-05-30 CN claimed
US-20250082827-A1 TRILAYERED BIOMIMETIC HYDROGEL SCAFFOLDS OF DUAL MICROENVIRONMENT AND PREPARATION METHOD AND APPLICATION THEREOF XINXIANG MEDICAL COLLEGE (CN) 2025-03-13 US claimed
CN-112831462-B Compositions, media and methods for inducing reprogramming of human cells to induced pluripotent stem cells 复旦大学 2022-10-18 CN claimed
CN-115054579-A Nanoparticle arthritis drug with active oxygen responsive gradient drug delivery and preparation method thereof 浙江大学 2022-09-16 CN claimed
CN-112807489-B Injectable acellular scaffold for cartilage repair and preparation method and application thereof 广东省人民医院 2022-09-13 CN claimed
US-11427808-B2 Method for serum-free culture of chondrocytes and serum-free culture medium REGENESIS SCIENCE CO., LTD. (JP) 2022-08-30 US claimed
WO-2022174071-A2 RECONSTITUTION OF EXTRACELLULAR MATRIXES FOR MUSCULOSKELETAL JOINT TISSUE REPAIR USING BIOMIMETIC BIOLOGIC AND SYNTHETIC FACTORS RHODE ISLAND HOSPITAL (US) 2022-08-18 WO claimed
US-20220257572-A1 METHODS OF TREATING EPILEPSY YALE UNIVERSITY 2022-08-18 US claimed
US-20220211683-A1 NOVEL MATERIAL FOR SKIN WOUND CLOSURE AND SCAR PREVENTION THE UNIVERSITY OF CHICAGO (US) 2022-07-07 US claimed
CN-114699562-A Hydrogel and preparation method and application thereof 南方科技大学 2022-07-05 CN claimed
CN-111588705-B Mesenchymal stem cell membrane camouflage magnetic drug-loaded nanoparticle and preparation method and application thereof 复旦大学附属华山医院 2022-07-05 CN claimed
CN-114652856-A Dual-protein delivery carrier programmed drug delivery system and preparation method thereof 西北大学 2022-06-24 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041819-A1 TUNABLE, BIOCOMPATIBLE, NANOPARTICLE-CROSSLINKED HYALURONIC ACID-TYPE I COLLAGEN HYDROGEL USING DIELS-ALDER CLICK CHEMISTRY FOR REGENERATIVE MEDICINE APPLICATIONS CD44, COL2A1, COL1A1 ALDH1A1 4/4885DHODH 604/4885MEN1 1752/4885
US-20220257572-A1 METHODS OF TREATING EPILEPSY FLNA, EPM2A, PFN1 ALDH1A1 2939/4885DHODH 3118/4885MEN1 889/4885
US-20260023070-A1 OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS SNCA, MAP1LC3B, MAPT ALDH1A1 2575/4885DHODH 2738/4885MEN1 4168/4885
US-20250295643-A1 METHODS OF TREATING EPILEPSY FLNA, EPM2A, PFN1 ALDH1A1 2939/4885DHODH 3118/4885MEN1 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.